Cargando…

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing

OBJECTIVE: To compare the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced triple-negative breast cancer (TNBC) and analyze the relationship between their efficacy and BRCA gene status. METHODS: Retrospectively analyze clinical data of 220 patients diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Nan, Li, Kun, Huang, Wenfa, Kong, Weiyao, Liu, Xiaoran, Shi, Weijie, Xie, Feng, Jiang, Hanfang, Song, Guohong, Di, Lijun, Wang, Quanren, Yu, Jianjun, Li, Huiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219102/ https://www.ncbi.nlm.nih.gov/pubmed/32410793 http://dx.doi.org/10.21147/j.issn.1000-9604.2020.02.03

Ejemplares similares

Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort
por: Liu, Xiaoran, et al.
Publicado: (2017)

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
por: Liu, Yaxin, et al.
Publicado: (2023)

Clinicopathological features and prognosis of patients with pregnancy‐associated breast cancer: A matched case control study
por: Zhang, Ruyan, et al.
Publicado: (2021)

Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report
por: Gui, Xinyu, et al.
Publicado: (2018)

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
por: Shao, Bin, et al.
Publicado: (2022)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
por: Metzger-Filho, Otto, et al.
Publicado: (2021)

Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing
por: Hirotsu, Yosuke, et al.
Publicado: (2015)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Kitahara, Miyuki, et al.
Publicado: (2021)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
por: Stossel, Chani, et al.
Publicado: (2023)

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
por: Vergote, I, et al.
Publicado: (2016)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study
por: Shao, Bin, et al.
Publicado: (2023)

A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report
por: Jiang, Lijuan, et al.
Publicado: (2021)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study
por: Chen, Xi, et al.
Publicado: (2023)

Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer
por: Nicolussi, Arianna, et al.
Publicado: (2019)

Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer
por: Ferreira, Elisa Napolitano, et al.
Publicado: (2019)

Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)
por: Jiang, Hanfang, et al.
Publicado: (2021)

BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing
por: Mafficini, Andrea, et al.
Publicado: (2016)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer
por: Huang, Xin, et al.
Publicado: (2020)

Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China
por: Lei, Wen, et al.
Publicado: (2020)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
por: Liang, Yuehua, et al.
Publicado: (2022)

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing
por: Bai, Han, et al.
Publicado: (2021)

High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients
por: Rashid, Muhammad Usman, et al.
Publicado: (2016)

Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing
por: Liang, Yi, et al.
Publicado: (2018)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Germline Mutational Landscape in Chinese Patients With Advanced Breast Cancer
por: Zhang, Jiayang, et al.
Publicado: (2022)

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer
por: Jia, Xiaomeng, et al.
Publicado: (2022)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
por: Stegel, Vida, et al.
Publicado: (2011)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5ql7qdlom1l56vqn2eqgs9khad